Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2014 (2014), Article ID 854163, 12 pages
http://dx.doi.org/10.1155/2014/854163
Research Article

Urine Annexin A1 as an Index for Glomerular Injury in Patients

1Graduate Institute of Aerospace and Undersea Medicine, National Defense Medical Center, Taipei, Taiwan
2Department of Animal Pharmacology, Development Center for Biotechnology, Taipei, Taiwan
3Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
4Division of Endocrinology & Metabolism, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
5Division of Nephrology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
6Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan

Received 27 June 2013; Accepted 20 October 2013; Published 20 January 2014

Academic Editor: Benoit Dugue

Copyright © 2014 Shuk-Man Ka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background. We recently demonstrated high urine levels of annexin A1 (ANXA1) protein in a mouse Adriamycin-induced glomerulopathy (ADG) model. Objective. To establish ANXA1 as a potential biomarker for glomerular injury in patients. Methods. A time-course study in the mouse ADG model, followed by renal tissues and urine samples from patients with various types of glomerular disorders for ANXA1. Results. Urinary ANXA1 protein was (1) detectable in both the ADG model and in patients except those with minimal change disease (MCD); (2) positively correlated with renal lesions in patients; and (3) early detectable in diabetes patients with normoalbuminuria. Conclusions. ANXA1 is a universal biomarker that is helpful in the early diagnosis, prognostic prediction, and outcome monitoring of glomerular injury. Measurement of urinary ANXA1 protein levels can help in differentiating MCD from other types of glomerular disorders.